Caplin Point Laboratories shares are likely to remain in focus on August 24 after the company received 10 observations from the US Food and Drug Administration (USFDA) following an inspection of its manufacturing facility in Tamil Nadu. The USFDA conducted an unannounced inspection of the company’s injectable and ophthalmic manufacturing facility located in Gummidipoondi. At the conclusion of the inspection, the regulator issued a Form 483 containing 10 observations. According to the company, the observations are procedural in nature and do not relate to data integrity. It also clarified that none of the observations were repeat observations. Caplin Point Laboratories said it is addressing the observations comprehensively and will submit its response to the USFDA within the stipulated timeframe. On the financial front, the company reported a strong performance for the quarter ended June 30, 2026. Revenue from operations rose 19.63% year-on-year to ₹610.36 crore, compared with ₹510.22 crore in the corresponding quarter of the previous year. Net profit increased 18.79% year-on-year. The USFDA observations and the company’s response will remain key factors for investors to monitor, while the strong growth in revenue and profit provides a positive backdrop for the stock.

#WatchOutFor

659 likes